Skip to main content Help with accessibility Skip to main navigation

Position Statements

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2015
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 12 - September - 2019

Medical camouflaging products must only be initiated by a healthcare professional that specialises in skin colour matching and appropriate application techniques.
Please note: these products must only be continued in primary care if the patient’s GP believes issuing such a prescription will continue to significantly reduce the impact of the patient’s medical condition.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2019

This guidance does not apply to the use of Sativex® (delta-9-etrahydrocannabinol and cannabidiol) oromucosal spray as an adjunct treatment for moderate to severe spasticity in multiple sclerosis.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Denosumab as a second-line treatment option for the prevention of Osteoporotic Fragility Fractures

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2016

The Lancashire Medicines Management Group does not recommend the prescribing of e-Cigarettes

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Date Posted: 01 - December - 2018

Prescribing recommendation: Where a DOAC is considered to be the most appropriate anticoagulant, edoxaban is to be used 1st line for patients with non-valvular AF unless there is a specific clinical reason not to do so.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2017

Empagliflozin (Jardiance®) for the treatment of type 2 Diabetes Mellitus, the EMPA REG OUTCOME study

 

Pending
Pending
Adopted
Pending
Adopted
Adopted
Pending
Pending
Date Posted: 01 - June - 2015

Buprenorphine and Fentanyl Patches for Pain should be reserved for use in patients with Chronic, Stable Pain who are Unable to Take or Tolerate Oral Medications (Including soluble tablets/liquids). If prescribed, it is recommended that the reason for use is documented on initiation and if appropriate patients are switched back to oral formulations at review.

Oral morphine remains the strong opioid of choice and should be used 1st line where appropriate.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2017

Where a proprietary biological medicine is indicated and biologically similar (biosimilar) medicine(s) to the reference product also exist the product with the lowest acquisition price should be used and charged to the commissioning organisation at the acquisition price (within licensed indications).

Product choices, including changes to treatment, for individual patients should be made following assessment by the responsible clinician taking into account patient choice.

Not adopted
Not adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - July - 2018
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - May - 2017
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Prescribing request from out-of-area specialists to Lancashire GPs where there is an inconsistency with the recommended local and out-of-area colour classification

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - July - 2018
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Not adopted
Date Posted: 01 - September - 2016

This position statement relates to the use of tapentadol MR for the following indications:

1. As a treatment option for intractable neuropathic pain in non-palliative care patients
2. As a treatment for nonspecific pain

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2016

Trans-anal Irrigation Systems are recommended for use within the Lancashire Health Economy for the treatment of Neurogenic Bowel Dysfunction and Non-Neurogenic Bowel Dysfunction including; chronic constipation and chronic faecal incontinence

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2017

This position statement covers all single-ingredient preparations of vitamin D prescribed within the Lancashire NHS health economy for the management of deficiency and insufficiency states. This document is not intended to provide full guidance for the use of vitamin D within the NHS in Lancashire. Local protocols should also be consulted where they exist.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - October - 2016

This policy only covers preparations without a product licence. Preparations with a product licence should only be prescribed for its licensed indications.

The prescribing of Vitamins, Minerals, Supplements, Herbal and Homeopathic medicines without a product licence in the NHS in primary care and secondary care in Lancashire is not recommended unless funding has been agreed for an individual product for a specific indication.